Zinner S H
Department of Medicine, Roger Williams General Hospital, Brown University, Providence, Rhode Island.
Clin Pharmacokinet. 1989;16 Suppl 1:59-64. doi: 10.2165/00003088-198900161-00010.
Enoxacin is a new fluoroquinolone that will be available as oral and intravenous preparations. This drug is bactericidal for a wide range of organisms, including Staphylococcus aureus, S. epidermidis, Enterobacteriaceae and Pseudomonas aeruginosa. In addition, Neisseria gonorrhoeae is exquisitely susceptible, as is Branhamella catarrhalis. The evaluation of the clinical activity of enoxacin is still relatively new, but published studies reveal a good deal of potential in the treatment of infections caused by susceptible bacteria in the urinary tract, upper and lower respiratory tracts, bones and joints, and the gastrointestinal tract. The general use of this drug has been associated with few adverse reactions. Further published data, as well as the results of comparative trials now in progress, will permit a thorough clinical evaluation of this useful drug.
依诺沙星是一种新型氟喹诺酮类药物，有口服和静脉制剂。该药对多种微生物具有杀菌作用，包括金黄色葡萄球菌、表皮葡萄球菌、肠杆菌科细菌和铜绿假单胞菌。此外，淋病奈瑟菌以及卡他莫拉菌对其极为敏感。依诺沙星临床活性的评估仍相对较新，但已发表的研究表明，在治疗由易感细菌引起的泌尿道、上呼吸道和下呼吸道、骨骼和关节以及胃肠道感染方面有很大潜力。该药物的普遍使用所引起的不良反应较少。更多已发表的数据以及正在进行的对比试验结果，将有助于对这种有用药物进行全面的临床评估。
